PLK3, polo like kinase 3, 1263

N. diseases: 52; N. variants: 1
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.010 AlteredExpression disease BEFREE Calcium-dependent inhibition of polo-like kinase 3 activity by CIB1 in breast cancer cells. 20473878 2011
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.010 AlteredExpression disease BEFREE Calcium-dependent inhibition of polo-like kinase 3 activity by CIB1 in breast cancer cells. 20473878 2011
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.010 AlteredExpression disease BEFREE In sharp contrast, PLK2, PLK3, and PLK4 messenger RNA and protein expression gradually declined from nontumorous liver to HCC, with the lowest levels being detected in HCC with shorter survival. 20112253 2010
CUI: C0002170
Disease: Alopecia
Alopecia 		0.010 Biomarker disease BEFREE Prevention of chemotherapy-induced alopecia by the anti-death FNK protein. 18164732 2008
CUI: C0003130
Disease: Anoxia
Anoxia 		0.010 Biomarker phenotype LHGDN Our results provide a new mechanism indicating that hypoxia/reoxygenation induces Plk3 activation instead of the JNK effect to directly phosphorylate and activate c-Jun, subsequently contributing to apoptosis in HCE cells. 18650425 2008
CUI: C0240803
Disease: Primary cerebral lymphoma
Primary cerebral lymphoma 		0.010 Biomarker disease BEFREE CNK/T-cell brain lymphoma associated with Epstein-Barr virus in a patient with AIDS. 17899696 2007
CUI: C0006413
Disease: Burkitt Lymphoma
Burkitt Lymphoma 		0.010 AlteredExpression disease BEFREE The related PLK1 and PLK3 (FNK/PRK) genes were overexpressed in BL cell lines lacking Snk/Plk2 expression, consistent with functional degeneracy among the Plk family. 16160013 2006
CUI: C0024299
Disease: Lymphoma
Lymphoma 		0.010 PosttranslationalModification group BEFREE Epigenetic inactivation of Plk2 via aberrant CpG methylation in the transcriptional regulatory elements of the gene is a common event in B cell neoplasia, whereas epigenetic inactivation of Plk3 is exceedingly rare in lymphomas. 16868416 2006
CUI: C0278764
Disease: Adult Burkitt Lymphoma
Adult Burkitt Lymphoma 		0.010 AlteredExpression disease BEFREE The related PLK1 and PLK3 (FNK/PRK) genes were overexpressed in BL cell lines lacking Snk/Plk2 expression, consistent with functional degeneracy among the Plk family. 16160013 2006
CUI: C0278879
Disease: Childhood Burkitt Lymphoma
Childhood Burkitt Lymphoma 		0.010 AlteredExpression disease BEFREE The related PLK1 and PLK3 (FNK/PRK) genes were overexpressed in BL cell lines lacking Snk/Plk2 expression, consistent with functional degeneracy among the Plk family. 16160013 2006
CUI: C0376545
Disease: Hematologic Neoplasms
Hematologic Neoplasms 		0.010 Biomarker group BEFREE Epigenetic inactivation implies a tumor suppressor function in hematologic malignancies for Polo-like kinase 2 but not Polo-like kinase 3. 16868416 2006
CUI: C0010633
Disease: Cystadenoma
Cystadenoma 		0.010 AlteredExpression disease BEFREE PLK 1 and PLK3 expression was low in normal ovarian surface epithelium and borderline tumours, with moderately higher expression levels in cystadenomas. 14970859 2004
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms 		0.010 GeneticVariation group BEFREE Forty lung tumor cell lines were used for single-strand confirmation polymorphism (SSCP) analysis and DNA sequencing to examine the mutational status of PLK3/PRK. 11746980 2001
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.010 AlteredExpression disease BEFREE These results suggest that although PLK3/PRK expression is downregulated in a majority of lung carcinoma samples, mutational inactivation of the coding sequence of the PLK3/PRK gene appears to be a rare event in lung cancer. 11746980 2001
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.010 Biomarker disease BEFREE Intron/exon organization and polymorphisms of the PLK3/PRK gene in human lung carcinoma cell lines. 11746980 2001
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung 		0.010 AlteredExpression disease BEFREE These results suggest that although PLK3/PRK expression is downregulated in a majority of lung carcinoma samples, mutational inactivation of the coding sequence of the PLK3/PRK gene appears to be a rare event in lung cancer. 11746980 2001
CUI: C0007097
Disease: Carcinoma
Carcinoma 		0.010 AlteredExpression group BEFREE We have previously shown that PRK expression is downregulated in a significant fraction of lung carcinomas. 10679924 2000
CUI: C0278996
Disease: Malignant Head and Neck Neoplasm
Malignant Head and Neck Neoplasm 		0.010 AlteredExpression disease BEFREE PRK, a cell cycle gene localized to 8p21, is downregulated in head and neck cancer. 10679924 2000
CUI: C3887461
Disease: Head and Neck Carcinoma
Head and Neck Carcinoma 		0.010 AlteredExpression disease BEFREE PRK, a cell cycle gene localized to 8p21, is downregulated in head and neck cancer. 10679924 2000
CUI: C0014544
Disease: Epilepsy
Epilepsy 		0.010 Biomarker disease BEFREE These findings indicate that chronic intake of CNK-602A in a dose that does not affect plasma levels of T3 and T4 inhibits tonic convulsions in SER and suggest that this drug may be an effective treatment for convulsive seizures in patients with epilepsy. 8603636 1996
CUI: C0036572
Disease: Seizures
Seizures 		0.010 AlteredExpression phenotype BEFREE These findings indicate that chronic intake of CNK-602A in a dose that does not affect plasma levels of T3 and T4 inhibits tonic convulsions in SER and suggest that this drug may be an effective treatment for convulsive seizures in patients with epilepsy. 8603636 1996
CUI: C0751494
Disease: Convulsive Seizures
Convulsive Seizures 		0.010 Biomarker phenotype BEFREE These findings indicate that chronic intake of CNK-602A in a dose that does not affect plasma levels of T3 and T4 inhibits tonic convulsions in SER and suggest that this drug may be an effective treatment for convulsive seizures in patients with epilepsy. 8603636 1996
CUI: C4048158
Disease: Convulsions
Convulsions 		0.010 AlteredExpression phenotype BEFREE These findings indicate that chronic intake of CNK-602A in a dose that does not affect plasma levels of T3 and T4 inhibits tonic convulsions in SER and suggest that this drug may be an effective treatment for convulsive seizures in patients with epilepsy. 8603636 1996